Requirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, Dr. Helmut Rockstroh

Similar documents
The International Pharmacopoeia Overview

EDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality

Challenges of Implementation of ICH Q 8

Technically Unavoidable Particles Profile (TUPPs) Guide

Implementing Quality Systems

PDA 71 Years of Connecting People, Science and Regulation

Submission of comments on Review of the Variations Guidelines (EC 1234/2008)

Analytical Methods and Sampling in the New Manufacturing Paradigm a Regulatory Perspective

Q8 and Q8 annex An industry Perspective

PMDA perspective on Quality by Design for pharmaceutical products

EDQM COUNCIL OF EUROPE CONFERENCE CERTIFICATION PROCEDURE : 20 YEARS OF EXPERIENCE March EDQM, Strasbourg, France ABSTRACTS

S1 TITAN Alloy LE Calibrations (P/N: )

ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective

bvparm2006.cif bvparm2006.cif Printed by Ram Seshadri

Importance of ICH Guidance in Fulfilling Process Validation Requirements

Connecting People, Science and Regulation

ICH Q-IWG Integrated Training Programme

QbD Application in Japan: PMDA Perspective

Quality Risk Management

EDQM Publications. Mrs Caroline Larsen Le Tarnec Head Public Relations & Documentation Division

Quality by Design, Clinical Relevance & Lifecycle Considerations

Global GMP Harmonisation A Japanese Perspective

Current Status and Challenges of Bilateral/Multilateral Meetings

CDER s Office of Pharmaceutical Quality (OPQ): Delivering on the 21 st Century Quality Goals

TECHNOLOGY TRANSFER:

The Process Analytical Technology Initiative: PAT and the Pharmacopeias

Claus Mortensen, Medicines Inspector. Danish Medicines Agency. Member of the EMEA PAT team

Terrence Tougas. Dennis Sandell

ALL RAW MATERIALS ARE NOT CREATED EQUAL.

Value Paper. Are you PAT and QbD Ready? Get up to speed

Progress in FDA s Drug Product Quality Initiative. Janet Woodcock, M.D. November 13, 2003

Reflection Paper on synergies between regulatory and HTA issues. DG SANTE Unit B4 Medical products: safety, quality, innovation

EU GMP Evolution or Revolution Scope and drivers for EU GMP changes. August Gordon Farquharson

Quality by Design. Innovate Design Development Create value. Correct definition of QbD and its relation to product and process development

VENUE. 2 DAY WORKSHOP On FDA Penalties for Regulatory Non-Compliance in the Pharmaceuticals Industry in Review , JAN San Diego CA

Quality by Design and OINDP. Today s Presentation

QUALITY: BRACKETING AND MATRIXING DESIGNS FOR STABILITY TESTING OF NEW VETERINARY DRUG SUBSTANCES AND MEDICINAL PRODUCTS

Association. Innovation in Medicines PDA: A Global. and Manufacturing. David Tainsh, GSK Keith Pugh, MHRA

Considerations for Leachables and Extractables in a Quality by Design Environment

Global Regulatory Update FDA, USP, EP and ICH Standards for Test Method Validation. Jane Weitzel

LED Display Product Data Sheet LTC-561CB-03J Spec No.: DS Effective Date: 06/02/2012 LITE-ON DCC RELEASE

Implementation of ICH Q8 and QbD An FDA Perspective

Office of Pharmaceutical Quality Key Quality Initiatives

WHO Regulatory Systems Strengthening Program

CERTIFICATE OF ANALYSIS

JUST SCRATCHING THE SERVICE

Software as a Medical Device (SaMD)

Brazilian industry s activities for international convergence. Walker Lahmann Director of External Trade at ABIFINA Executive Director at Eurofarma

First Pass Sampling on Vranje-South Project Defines Li-B Anomalies

EDQM Conference. Quality of Medicines in a Globalised World: Dreams and Reality

ICH Q8 / ICH Q11 Training Course

Polymer Comparisons for the Storage and Trace Metal Analysis of Ultrapure Water with the Agilent 7500cs ICP-MS Application

Guidance for Industry

Quality assurance in the supply chain for pharmaceuticals from the WHO perspective

WHITE PAPER FACILITY FOCUS: GMP Facility Modernization. By: David M. Marks, P.E.

TABLE OF CONTENTS DUPONT TYVEK MEDICAL PACKAGING TRANSITION PROJECT (MPTP) EXECUTIVE SUMMARY JUNE 2016 THE FINAL PHASE EXECUTIVE SUMMARY 2

February 5, 2010 VIA ELECTRONIC SUBMISSION

European Commission Health and Consumers Directorate General, Brussels

CERTIFICATE SD SAMPLE PREPARATION ANALYTICAL PROCEDURES. Signature: Colin Ramshaw, Vancouver Laboratory Manager

Future of Pharmaceutical Quality and the Path to Get There

Guideline for Technology Transfer (Draft)

Convergence and Differentiation within the Framework of European Scientific and Technical Cooperation on HTA

ICH Q8, 9 & 10 and the Impact on the QP

Quality Regulation under Revised Pharmaceutical Affair Law

Assay of sodium thiosulfate and ionic impurities in sodium thiosulfate using ion chromatography

DTU DANCHIP an open access micro/nanofabrication facility bridging academic research and small scale production

Beware the non-critical excipient

PHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW

FDA s Evolving Approach to Pharmaceutical Quality

Building Toward a Modern Pharmaceutical Manufacturing Sector: Encouraging Development and Adoption of Emerging Technology

OMCL Network of the Council of Europe GENERAL DOCUMENT

Stop Worrying About Interferences With These ICP-OES Solutions

API hapis High Potency Active Pharmaceutical Ingredients. High Potency Active Pharmaceutical Ingredients. Innovation made. Easy.

EXCIPIENTS KNOWLEDGE MANAGEMENT: CHALLENGES & SOLUTIONS

peace of mind For from development to commercial supply

Overview and Version 3.1.0

Natural Health Products Directorate Update

SYNONYMS: Bee wax, Cera alba, White Wax, Wax, Cera flava, Yellow Wax

Advisory Board. Advisory Board. Advisory Board (1) GMP Manual (Up05) Maas & Peither AG GMP Publishing

CMC Topics and PMDA s activities Yoshihiro Matsuda, Ph.D.

- Quality Driven Process -

LED Display Product Data Sheet LTS-4802KR-01J Spec No.: DS Effective Date: 09/26/2009 LITE-ON DCC RELEASE

QUALITY REQUIREMENTS FOR ARTEMISININ AS A STARTING MATERIAL IN THE PRODUCTION OF ANTIMALARIAL ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)

From API to Formulated Product

Midwest Regional Forum. Work Smarter Not Harder Leveraging Prior Knowledge to Accelerate CMC Programs

CURRICULUM VITAE. Environment, Occupational Health and Safety)

Manufacture of medicinal products in Italy: challenges for the Italian Medicines Agency

Continuous Manufacturing, Emerging Technology and the Office of Pharmaceutical Quality

Timescales for Change A Look at Innovation in the Pharmaceutical Industry

Annual report of the Good Manufacturing and Distribution Practice Inspectors Working Group 2017

Financing projects & exploration in Russia

Challenges, benefits, case study

ISO/TC 130 N 2076 ISO/TC 130/WG 4 N 686. Minutes-WG4_43_ _Yogyakarta. Date of document Expected action. Source ISO/TC 130/WG 4

USP Research & Innovation Program

APIs global business developments

Analytical Development Labs

DSM Sinochem Pharmaceuticals

PDA: A Global. Association. Points to Consider in the. Manufacturing of Sterile Products

Issues in Emerging Health Technologies Bulletin Process

Progressive Licensing and the Modernization of the Canadian Regulatory Framework

Transcription:

Requirements in Other Countries PQRI+USP EI Workshop; Rockville, MD, 2015 Dr. Helmut Rockstroh

Overview Introduction - Scope Pharmacopoeial + HA Positions Examples / Case Studies Discussion 2

Introduction: Repetition of Q3D Basics ICH Q3D applies to: human drug products. new finished drug products Does not apply to: IMP.. As the commercial process is developed,..this guideline can be useful. Components, i.e. Drug Substance/ Excipients Application of Q3D to existing products is not expected prior to 36 months after publication of the guideline by ICH. 3

Requirements: Same or Different for Suppliers / DP Maker / HA? Communication strategy - formalistic - scientific Cultural factors national/regional DP / DS / Supplier Supplier: DP cgmps / Regulatory requirements vs : SPU requirements Other markets HA: Training issues - National policy - Misalignment DP Maker: - Purpose? - Requirements - Asking too much? 4

Pharmacopoeias: Implementation Scope EDQM / EMA.. it is planned to delete cross-references to the wet chemical tests for heavy metals described in chapter 2.4.8 from all individual monographs (except for monographs on products for veterinary use only). (EPCOM Bulletin July 2014). the choice of an appropriate analytical strategy will be left to the user, in line with.. ICHQ3D. Chapter 2.4.20 (guidance). 151 EPCOM (17. Mar) has confirmed the 36 months implementation period for legacy products ICH. June 2016 for NDAs. JP plans to retain the old Heavy Metals Test Even after implementation of ICHQ3D because JP is used for many purposes (Informal quote JPMA). 5

Pharmacopoeias (continued) ChP No activities i.e. requirements with regard to moving towards a change to classical HM testing to be expected before 2020. USP <232>/<233> The limits indicated in this chapter are not required for articles intended only for veterinary use and conventional vaccines.. When testing is done to demonstrate compliance,..minimally include As, Cd, Pb, and Hg in the Target Element evaluation. Unique!? USP also announces a revision to General Chapter <231> Heavy Metals and its references to delay omission until January 1, 2018 6

Examples: DP NDA Submission HA Requests APEC 2014 Applicant (NDA) received a request from HA asking for addition of a test for HMs (limit test) on both DS and Product despite the presentation of extensive data showing absence below Q3D limits (<<30%) in both API and final intermediate. LATAM 2013 As soon as the USP General Chapters were official we were asked for data. We explained that the General Chapters were not referenced in any USP monograph items and would not be implemented until USP General Notice was official. We also explained that ICH Q3D was only at step 2 at the time and there was no implementation time line. We were not asked again for any data. 7

Example: IPEC EI Questionnaire - original From a DP maker to an excipient supplier Request: Please note if any metals are intentionally used in the manufacturing process in the Comments column. Material = Substance for Pharmaceutical Use (SPU) 8

Example: Japanese DP maker EI Questionnaire: 1 -- Why mined? Culture?? 2 Language?? -- inorganic reagents + raw materials 5 3 Language?? -- 3 latest batches!? -- Controls? = Specs? Language?? 6 Culture?? -- testing site? 4 Culture?? -- test method?* -- LOD not LOQ? * Also part of IPEC Questionnaire 9

DP maker EI Questionnaire (2) Excipient maker s view IPEC Questionnaire sent to Excipient maker by DP maker from Japan: Questionnaire was modified: Unknown was deleted (DP maker: There can be no Unknown ) DP maker wanted to know whether the source of any of these elements was a mineral (Supplier: It did not make sense to ask that) DP maker asked for statements that the elements in ICH Q3D were not intentionally added and... not being used in any form as a catalyst when that information was already covered in the information provided. 10

For Discussion What are your views? / or 1. Does Unknown exist? 2. What (if anything) is special about mined material? 3. Of what value to the DP maker is it to know which test method was used? 4. LOD/ LOQ? 5. Test site? 6. What s missing? Recommendations? 1. 2. 3. 4. 5. 6. 11

Conclusions The major Pharmacopoeias have moved closer to harmonized requirements, but there is some way to go: EP implementation for NDA: June 2016; legacy: End 2017 JP way forward with old HM test/ implementation timelines unclear USP: minimally include As,Cd,Hg,Pb in Target Element evaluation Implementation Jan. 1. 2018 The dialogue between DP makers / Suppliers / HA s is still evolving Industry would like the Authorities to be aligned. Would industry in turn utilize a standard approach amongst themselves? (Re: Supplier Questionnaire) 12

Acknowledgements Yosuke Momose, Chugai, Japan David Schoneker, Colorcon, USA Mark Schweizer, Novartis, USA Andrew Teasdale, Astra Zeneca, UK Phyllis Walsh, Merck, USA Priscilla S Zawislak, Ashland, USA 13

Thanks 14

Impacted Monographs EP: The list of all impacted monographs will be published in Pharmeuropa, in January 2015 (issue 27.1). It is currently foreseen to publish the revised individual monographs in the 9th edition with an implementation date of 1 January 2017. Listing postponed to issue 27(2) (April 1) USP: List of affected monographs 15

Modes of Contamination Generalized from Q3D Drug Substance Water Excipients Environment Elemental Impurities in Drug Product Containers Closures Manufacturing Equipment Primary Packaging Materials 16

Elements to include in the Risk Assessment If not intentionally added (ICHQ3D) Element Class If intentionally added (all routes) Oral Parenteral Inhalation As 1 yes yes yes yes Cd 1 yes yes yes yes Hg 1 yes yes yes yes Pb 1 yes yes yes yes Co 2A yes yes yes yes Ni 2A yes yes yes yes V 2A yes yes yes yes Ag 2B yes no no no Au 2B yes no no no Ir 2B yes no no no Os 2B yes no no no Pd 2B yes no no no Pt 2B yes no no no Rh 2B yes no no no Ru 2B yes no no no Se 2B yes no no no Tl 2B yes no no no Ba 3 yes no no yes Cr 3 yes no no yes Cu 3 yes no yes yes Li 3 yes no yes yes Mo 3 yes no no yes Sb 3 yes no yes yes Sn 3 yes no no yes 17

Doing now what patients need next 18